Jerry D Cockerell, DO in Kingston, OK - Orthopaedic Surgery

Jerry D Cockerell, DO is a Orthopaedic Surgery physician based in Kingston, Oklahoma. Jerry D Cockerell is licensed to practice in Oklahoma (license number 2853) and his current practice location is Hc 72 Box 329, Kingston, Oklahoma. He can be reached at his office (for appointments etc.) via phone at (580) 564-2446.

NPI number for Jerry D Cockerell is 1093009920 and his current mailing address is Hc 72 Box 329, Kingston, Oklahoma. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1093009920.

Contact Information

	Jerry D Cockerell, DO
	Hc 72 Box 329, Kingston, OK 73439-8521
	(580) 564-2446
	Not Available

Physician's Profile

Full Name	Jerry D Cockerell
Gender	Male
Speciality	Orthopaedic Surgery
Location	Hc 72 Box 329, Kingston, Oklahoma
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1093009920
Provider Enumeration Date: 06/08/2011
Last Update Date: 06/08/2011

Medical Identifiers

Medical identifiers for Jerry D Cockerell such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1093009920	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207X00000X	Orthopaedic Surgery	2853 (Oklahoma)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Jerry D Cockerell is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Jerry D Cockerell, DO Hc 72 Box 329, Kingston, OK 73439-8521 Ph: (580) 564-2446	Jerry D Cockerell, DO Hc 72 Box 329, Kingston, OK 73439-8521 Ph: (580) 564-2446

News Archive

Systagenix announces U.S. launch of EPIFIX amniotic membrane allograft

Systagenix, announced today that it will launch EPIFIX in the United States in March as part of a global distribution agreement reached with MiMedx Group, Inc.

IQWiG tests suitability of AHP method for identifying preferences of patients regarding treatment goals

It is more important to patients suffering from depression that they show a noticeable response to treatment in the first place than being completely cured. It is exactly the opposite in physicians treating people with this disease: they consider remission to have higher priority than response.

Savient Pharmaceuticals announces filing of KRYSTEXXA BLA resubmission on track

Savient Pharmaceuticals, Inc. provided an update on its activities directed toward the resubmission of its Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy and reaffirmed its belief that it continues to be on track for the filing of the BLA resubmission for KRYSTEXXA in the first quarter of 2010.

Mobile phones join the fight against youth depression

Mobile phones are to be used in a 400 person study to determine how youth depression starts and develops. The researchers hope to use the results to create a mobile phone program to act as an early warning system for at-risk young people.

Jerry D Cockerell, DO - Orthopaedic Surgery in Kingston, OK